Expression pattern of key micro<scp>RNA</scp>s in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Fallah, Parviz; Amirizadeh, Naser; Poopak, Behzad; Toogeh, Gholamreza; Arefian, Ehsan; Kohram, Fatemeh; Rad, Seyed Mohammad Ali Hosseini; Kohram, M.; Naghadeh, H. Teimori; Soleimani, Masoud

doi:10.1111/ijlh.12351

Cited by 36 publications

(27 citation statements)

References 47 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, low miR-188-5p expression was associated with longer overall survival and event free survival for CN-AML [14]. miR-16-1 expression was used as a good candidate for prognosis prediction in chronic myeloid leukemia [15]. In addition, miR-29c is of important prognostic value and influences response to azacitidine treatment in older AML patients [16].…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia

Wang

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

MYH9 expression has previously been demonstrated as an independent predictor of clinical outcome in solid tumors. However, the prognostic relevance of MYH9 expression in acute myeloid leukemia is still unclear. Here, we found high MYH9 expressers were seen more frequently in females and more frequently in M4 morphology. We also found high MYH9 expressers had lower percentage of bone marrow blasts. In addition, overexpression of MYH9 was associated with an inferior overall survival. Notably, distinct microRNA signatures were seen in high MYH9 expressers. These results were also validated in an independent cohort of AML patients using the published data. In conclusion, gene of MYH9 expression might serve as a reliable predictor for overall survival in AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia

Wang

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…The miR‐17/92 cluster is a promising biomarker for disease progression as the overexpression of the cluster was reported in CD34 + cells from patients in CP, but not in BP [Venturini et al, ]. Similar findings were also reported in 50 CP CML patients using reverse transcription polymerase chain reaction analysis, showing increased expression of miR‐17 and miR‐20a [Fallah et al, ]. Although these findings are promising, they conflict with previously published microarray expression results showing increased expression of miR‐17 , miR‐19a , miR‐19b , and miR‐20a during the BP of CML [Machova Polakova et al, ].…”

Section: Mirnas In CMLmentioning

confidence: 86%

“…Further, evidence for down‐regulation of miR‐150 as a diagnostic biomarker of CML was shown in a study that used a reverse transcription polymerase chain reaction approach on 50 newly diagnosed CP CML patient samples, and found significant down‐regulation of miR‐150 [Fallah et al, ]. A study in 2010 performed a microarray analysis on 10 CP CML patient samples and further validated the potential of miR‐150 as a biomarker for CML diagnosis [Flamant et al, ].…”

Section: Mirnas In CMLmentioning

confidence: 99%

“…Several groups have found a class of regulatory genes, the microRNAs (miRNAs) that are misexpressed in CML [Godley, ; Venturini et al, ; Agirre et al, ; Bueno et al, ; San Jose‐Eneriz et al, ; Eiring et al, ; Flamant et al, ; Zimmerman et al, ; Chim et al, ; Lopotova et al, ; Machova Polakova et al, ; Suresh et al, ; Rokah et al, ; Scholl et al, ; Yu et al, ; Li et al, ; Gebauer et al, ; Joshi et al, ; Kaymaz et al, ; Taverna et al, ; Xiong et al, ; Xishan et al, ; Xu et al, ; Fallah et al, ; Hershkovitz‐Rokah et al, ], opening new avenues into CML biomarker research.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miRNAs as Biomarkers in Chronic Myelogenous Leukemia

Kotagama

Chang

Mangone

2015

Drug Development Research

View full text Add to dashboard Cite

Strategy, Management and Health PolicyEnabling Technology, Genomics, ProteomicsPreclinical ResearchPreclinical Development Toxicology, Formulation Drug Delivery, PharmacokineticsClinical Development Phases I-III Regulatory, Quality, ManufacturingPostmarketing Phase IV Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.

show abstract

“…Like other coding genes, miRNAs are also overexpressed or down-regulated in cancers. So, they are considered to be ideal candidates for cancer therapy, prognosis and even diagnosis (Fallah et al, 2015;Kouhkan et al, 2015;Mobarra et al, 2015a;Rad et al, 2013;Soufi-Zomorrod et al, 2016). One of the best well-studied miRNAs with tumor-suppressor function is miR34a.…”

Section: Introductionmentioning

confidence: 99%

Synergistic effect of microRNA and albumin-bound nanoparticles for inhibition of glioblastoma cancer cell proliferation

Shariatnasery

Irani

Soleimani

et al. 2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The functional significance of upregulation miR-34a in combination with albumin-bound paclitaxel nanoparticles in U251 glioblastoma cell line has been evaluated. The MTT assay determined that miR-34a and albumin-bound paclitaxel nanoparticles can reduce cell viability, but the combination of both factors has a stronger effect on cell viability. The application of qRT-PCR has demonstrated that the transduction of miR-34a could lead to exogenous upregulation of miR-34a level and downregulation of SURVIVIN. Moreover, treatment of U251 cells with miR-34a and nanoparticles together considerably inhibit SURVIVIN expression compared to miR-34a and nanoparticles alone. Flow cytometry showed that upon miR-34a overexpression cell cycle arrested in G1 phase, while treatment with nanoparticles increased the cell population in G2 phase. Upregulation of miR-34a along with treatment with nanoparticles elevated the number of cells arrested in G1/ G2 phases of the cell cycle. Expression of miR-34a with albumin-bound paclitaxel nanoparticles reduced cell viability, downregulated SURVIVIN and enhanced cell cycle arrest in G1/G2 phases. Thus, the upregulation of miR-34a with these nanoparticles are potential candidates therapeutic for glioblastoma cancer.

show abstract

Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Abstract: These results show that very few miRNAs alone would be good candidates for CML diagnosis independently of conflicting results, but together could be an additional tool for CML diagnosis. Moreover, miRNAs might be good candidates for prognosis prediction and CML therapy.

Cited by 36 publications

References 47 publications

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia

miRNAs as Biomarkers in Chronic Myelogenous Leukemia

Synergistic effect of microRNA and albumin-bound nanoparticles for inhibition of glioblastoma cancer cell proliferation

Contact Info

Product

Resources

About